Use of the HSP 110 Peptide Binding Protein for the Development of New Breast Cancer Vaccines
Abstract
Several studies have confirmed that certain stress proteins can function as potent vaccines against a specific cancer when purified from the same tumor. We have hypothesized in our application that hsp110 may be an excellent candidate for cancer vaccines. In this second annual report, we describe the studies of the vaccine potential of hspl10 and its ER homologue grp170, two long recognized but unstudied stress proteins. Vaccination with these two HSPs purified from Meth A fibrosarcoma caused the complete tumor regression. A significant growth inhibition of Colon 26 tumor was also seen in the mice immunized with hsp110 or grp170 from Colon 26 tumor. In addition, HSP immunization significantly extended the life span of tumor-bearing mice when applied after tumor transplantation. A tumor specific CTL response developed in the mice immunized with tumor derived hsp110 or grp170. Furthermore, treatments of the mice with bone marrow derived dendritic cells pulsed with hsp110 or grp170 from tumor also elicited a strong anti-tumor response. Lastly, we showed that mild, fever-like hyperthermic conditions, which have been shown to stimulate other immunological functions, also stimulate the vaccine efficiency of hsp110 as well as hsc70, but not grp170. These studies indicate that hspl10 and grp170 can be used in heat shock protein-based cancer immunotherapy, that dendritic cells can be used to efficiently mediate this therapeutic approach, and that fever-level hyperthermia can significantly enhance the vaccine efficiency of heat shock proteins hsc70 and hspl10.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADA389335
Entities
People
- John Subjeck
Organizations
- Health Research, Incorporated